The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Vaccines for the elderly: current use and future challenges
Open accessAbstract
Age-related changes of the immune system contribute to increased incidence and severity of infections in the elderly. Vaccination is the most effective measure to prevent infections and vaccination recommendations in most countries include specific guidelines for the elderly. Vaccination against influenza and Streptococcus pneumoniae is usually recommended for persons with underlying diseases and for the elderly with heterogeneous age limits between ≥ 50 years and ≥ 65 years. Some countries also recommend vaccination against herpes zoster. Several vaccines are recommended for all adults, such as regular booster shots against tetanus/diphtheria/pertussis/polio, or for specific groups, e.g. vaccination against tick-borne encephalitis in endemic areas or travel vaccines. These are also relevant for the elderly. Most currently used vaccines are less immunogenic and effective in the elderly compared to younger adults. Potential strategies to improve their immunogenicity include higher antigen dose, alternative routes of administration, and the use of adjuvants, which were all implemented for influenza vaccines, and induce moderately higher antibody concentrations. Research on universal vaccines against influenza and S. pneumoniae is ongoing in order to overcome the limitations of the current strain-specific vaccines. Respiratory syncytial virus causes significant morbidity in the elderly. Novel vaccines against this and other pathogens, for instance bacterial nosocomial infections, have tremendous potential impact on health in old age and are intensively studied by many academic and commercial organizations. In addition to novel vaccine developments, it is crucial to increase awareness for the importance of vaccination beyond the pediatric setting, as vaccination coverage is still far from optimal for the older population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Influenza causes approximately 100,000 hospitalizations and 36,000 deaths annually in the USA, which occur mainly in persons over the age 65 years [6, 7].”
BackgroundEfficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789 · cited 1×
“Meta-analyses have estimated clinical benefits of influenza vaccination, and it can be concluded that protection is lower in older than in young adults [13, 14].”
BackgroundPolysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
Bonten, M. J. M., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C. H., van Deursen, A. M. M., Sanders, E. A. M., Verheij, T. J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408544 · Cited by 1,248 · cited 1×
“001) fewer first episodes of vaccine-type invasive pneumococcal disease occurred in the vaccine group compared to placebo [25].”
BackgroundEfficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Antibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315727 · Cited by 876 · cited 1×
“Several strategies to improve influenza vaccines for the elderly led to the licensure of vaccines containing the oil-in-water emulsion adjuvant MF59 [15] or 60 μg instead of 15 μg of hemagglutinin protein per dose [16], and of a vaccine administered via the intradermal instead of the intramuscular route [17].”
MethodWaight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70044-7 · Cited by 589
Haynes, L., Eaton, S. M., Burns, E. M., Randall, T. D., & Swain, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2433717100 · Cited by 270 · cited 1×
“Impaired memory generation late in life has been demonstrated in animal models [59, 60] and therefore the success of primary vaccination late in life might be limited.”
BackgroundHolland, D., Booy, R., Looze, F. D., Eizenberg, P., McDonald, J., Karrasch, J., McKeirnan, M., Salem, H., Mills, G., Reid, J., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/590434 · Cited by 254 · cited 1×
“Several strategies to improve influenza vaccines for the elderly led to the licensure of vaccines containing the oil-in-water emulsion adjuvant MF59 [15] or 60 μg instead of 15 μg of hemagglutinin protein per dose [16], and of a vaccine administered via the intradermal instead of the intramuscular route [17].”
MethodYao, X., Hamilton, R. G., Weng, N.-P., Xue, Q.-L., Bream, J. H., Li, H., Tian, J., Yeh, S.-H., Resnick, B., Xu, X., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.077 · Cited by 189
Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza
Beyer, W. E. P., McElhaney, J., Smith, D. J., Monto, A. S., Nguyen-Van-Tam, J. S., & Osterhaus, A. D. M. E. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.063 · Cited by 175 · cited 1×
“Meta-analyses have estimated clinical benefits of influenza vaccination, and it can be concluded that protection is lower in older than in young adults [13, 14].”
BackgroundLeroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis497 · Cited by 147
Ansaldi, F., Bacilieri, S., Durando, P., Sticchi, L., Valle, L., Montomoli, E., Icardi, G., Gasparini, R., & Crovari, P. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.019 · Cited by 134 · cited 1×
“Interestingly, MF59-adjuvanted vaccines induce substantially higher antibody responses against heterologous vaccine strains [18, 19], and this broader neutralizing activity probably contributes to the higher clinical efficacy observed with the adjuvanted vaccine.”
BackgroundImmunogenicity of combined hepatitis A and B vaccine in elderly persons
Wolters, B., Junge, U., Dziuba, S., & Roggendorf, M. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00399-2 · Cited by 116
Kaml, M., Weiskirchner, I., Keller, M., Luft, T., Hoster, E., Hasford, J., Young, L., Bartlett, B., Neuner, C., Fischer, K.-H., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.037 · Cited by 98
Weinberger, B., Schirmer, M., Matteucci Gothe, R., Siebert, U., Fuchs, D., & Grubeck-Loebenstein, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082967 · Cited by 61
Self-citationRidda, I., Yin, J. K., King, C., Raina MacIntyre, C., & McIntyre, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.079 · Cited by 48
Cited by
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D’Agnano, V., Komici, K., Mazzarella, G., Parrella, R., & Bianco, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01631-y · Cited by 420
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Immunoinformatics and Vaccine Development: An Overview
Oli, A. N., Obialor, W. O., Ifeanyichukwu, M. O., Odimegwu, D. C., Okoyeh, J. N., Emechebe, G. O., Adejumo, S. A., & Ibeanu, G. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s241064 · Cited by 281
Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149
Alsaleh, G., Panse, I., Swadling, L., Zhang, H., Richter, F. C., Meyer, A., Lord, J., Barnes, E., Klenerman, P., Green, C., et al. (2020) · eLife · doi:10.7554/elife.57950 · Cited by 120
Metadata
- Authors
- Weinberger, B.
- Venue
- Immunity & Ageing
- Published
- 2018-01-22
- Volume
- 15
- Issue
- 1
- Pages
- 3-3
- ISSN
- 1742-4933 (ISSN-L)
- OpenAlex
- W2802620527
- Cited by
- 160
- References
- 19
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.